Kaleido Financial Statements From 2010 to 2022

KLDO -  USA Stock  

USD 2.23  0.13  6.19%

Kaleido Biosciences financial statements provide useful quarterly and yearly information to potential Kaleido Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kaleido Biosciences financial statements helps investors assess Kaleido Biosciences' valuation, profitability, and current liquidity needs.
We have found fifty-nine available fundamental ratios for Kaleido Biosciences, which can be analyzed and compared to other ratios and to its peers in the industry. We recommend to check Kaleido Biosciences' last-minute fundamental drivers against the all of the trends between 2010 and 2022.
Kaleido Biosciences Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 88.34 Million. Average Equity is expected to rise to about 43.8 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (74.8 M).

Kaleido Financial Statements 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 3.5 M or Operating Expenses of 85.1 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.76 or Current Ratio of 3.93. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets73.2 M68.2 M47.3 M
Increasing
Slightly volatile
Cash and Equivalents62.4 M55.6 M42.1 M
Increasing
Slightly volatile
Property Plant and Equipment Net8.3 M9.7 M4.1 M
Increasing
Slightly volatile
Trade and Non Trade Receivables40.3 K40.5 K44.3 K
Decreasing
Slightly volatile
Trade and Non Trade PayablesM6.2 M2.2 M
Increasing
Slightly volatile
Total Liabilities41.3 M44.7 M27.8 M
Increasing
Slightly volatile
Shareholders Equity25.4 M23.6 M(25.2 M)
Increasing
Slightly volatile
Current Assets62.3 M56 M41.9 M
Increasing
Slightly volatile
Assets Non Current10.9 M12.2 M5.3 M
Increasing
Slightly volatile
Current Liabilities16.2 M19.2 MM
Increasing
Slightly volatile
Liabilities Non Current25.1 M25.5 M19.8 M
Increasing
Slightly volatile
Total Debt23 M24.2 M17.1 M
Increasing
Slightly volatile
Debt Current2.4 M2.4 M2.6 M
Decreasing
Slightly volatile
Debt Non Current21 M21.1 M16.5 M
Increasing
Slightly volatile
Shareholders Equity USD25.4 M23.6 M(25.2 M)
Increasing
Slightly volatile
Cash and Equivalents USD62.4 M55.6 M42.1 M
Increasing
Slightly volatile
Total Debt USD23 M24.2 M17.1 M
Increasing
Slightly volatile

Kaleido Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues872.4 K877.5 K959.6 K
Decreasing
Slightly volatile
Selling General and Administrative Expense24.7 M27.5 M12.7 M
Increasing
Slightly volatile
Research and Development Expense60.4 M64.4 M35 M
Increasing
Slightly volatile
Operating Expenses85.1 M91.8 M47.7 M
Increasing
Slightly volatile
Interest Expense3.5 M3.2 M1.2 M
Increasing
Slightly volatile
Weighted Average Shares41.5 M38.5 M13.8 M
Increasing
Slightly volatile
Weighted Average Shares Diluted41.5 M38.5 M13.8 M
Increasing
Slightly volatile
Revenues USD872.4 K877.5 K959.6 K
Decreasing
Slightly volatile
Gross Profit872.4 K877.5 K959.6 K
Decreasing
Slightly volatile

Kaleido Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing46.9 M36.4 M53.5 M
Increasing
Very volatile
Issuance Repayment of Debt Securities (135.8 K)(132.3 K)6.5 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares40.8 M46.6 M17 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(23.2 M)(22.6 M)13.9 M
Decreasing
Slightly volatile
Share Based Compensation12.1 M14.6 M4.7 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion1.7 M2.1 M790.4 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(2.14)(2.08)0.0226
Decreasing
Slightly volatile
Gross Margin0.890.90.9842
Decreasing
Slightly volatile
Asset Turnover0.01250.01260.0138
Decreasing
Slightly volatile
Sales per Share0.02590.02610.0285
Decreasing
Slightly volatile
Price to Sales Ratio279281307
Decreasing
Slightly volatile
Price to Book Value15.1818.376.1846
Increasing
Slightly volatile
Debt to Equity Ratio2.352.180.2155
Increasing
Slightly volatile
Current Ratio3.932.636.3503
Decreasing
Slightly volatile
Book Value per Share0.760.7(7.1572)
Increasing
Slightly volatile
Tangible Assets Book Value per Share1.641.66.1503
Decreasing
Slightly volatile

Kaleido Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization336.7 M376.6 M196.1 M
Increasing
Slightly volatile
Enterprise Value284.7 M335.3 M133.4 M
Increasing
Slightly volatile
Invested Capital17.6 M17.6 M14.2 M
Increasing
Slightly volatile
Average Equity43.8 M40.6 M(33.3 M)
Increasing
Slightly volatile
Average Assets88.3 M82.3 M66.8 M
Increasing
Slightly volatile
Invested Capital Average21.6 M24 M14.4 M
Increasing
Slightly volatile
Tangible Asset Value73.2 M68.2 M47.3 M
Increasing
Slightly volatile
Working Capital46.1 M36.9 M33.9 M
Increasing
Slightly volatile

Kaleido Fundamental Market Drivers

Short Percent Of Float10.54%
Forward Price Earnings-0.99
Shares Short Prior Month2.2M
Average Daily Volume Last 10 Day130.64k
Average Daily Volume In Three Month142.55k
Date Short Interest15th of December 2021
Fifty Day Average3.1776
Two Hundred Day Average5.4784

Kaleido Upcoming Events

Upcoming Quarterly Report2nd of March 2022
Next Earnings Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End2nd of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Revenues877.5 K872.4 K
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Kaleido Biosciences Investors Sentiment

The influence of Kaleido Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kaleido. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Kaleido Biosciences Implied Volatility

    
  366.88  
Kaleido Biosciences' implied volatility exposes the market's sentiment of Kaleido Biosciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Kaleido Biosciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Kaleido Biosciences stock will not fluctuate a lot when Kaleido Biosciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kaleido Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kaleido Biosciences' short interest history, or implied volatility extrapolated from Kaleido Biosciences options trading.

Current Sentiment - KLDO

Kaleido Biosciences Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Kaleido Biosciences. What is your trading attitude regarding investing in Kaleido Biosciences? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.